MegaPro, Outstanding performance from MegaPro Biomedical, the contrast agent has received approval by FDA for Phase II of clinical trial

The MPB-1523 MRI contrast agent developed by “MegaPro Biomedical”, a start-up from ITRI, showed rapid progress. Despite having established for only 3 years, MegaPro Biomedical obtained the approval from the US Food and Drug Administration (FDA) to conduct Phase II of the clinical trial for its contrast agent. The contrast agent has passed the Investigational […]